Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

2020 Year in Review - Multiple Myeloma

2020 Year in Review - Multiple Myeloma - Multiple Myeloma
Related Items
Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in Multiple Myeloma
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 30, 2019 in FDA Updates, Multiple Myeloma, In the News
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
Web Exclusives published on August 1, 2019 in Multiple Myeloma
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Web Exclusives published on March 6, 2019 in Immunotherapy, Multiple Myeloma
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Web Exclusives published on October 9, 2018 in Immunotherapy, Multiple Myeloma
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Updates, Multiple Myeloma
Last modified: November 29, 2020